Table 2.
HI antibody responses (GMT and GMR) against H5N1 at Day 1, Day 22, Day 43, and Day 183 by age group.
| 18 to <65 Years | ≥65 Years | Total Population | ||||
|---|---|---|---|---|---|---|
| aH5N1c | Placebo | aH5N1c | Placebo | aH5N1c | Placebo | |
| Day 1, n | 1116 | 372 | 1133 | 367 | 2249 | 739 |
| GMT (95% Cl) |
13.5 (12.8–14.2) |
13.7 (12.5- 15.0) |
20.5 (19.4–21.8) |
20.6 (18.6–22.7) |
16.6 (16.0–17.3) |
16.7 (15.6–17.9) |
| Day 22, n | 1115 | 370 | 1130 | 366 | 2245 | 736 |
| GMT (95% Cl) |
50.6 (47.6–53.8) |
11.6 (10.4–12.9) |
42.4 (40.0–45.0) |
14.5 (13.1–16.0) |
46.4 (44.5–48.4) |
13.0 (12.1–14.0) |
| GMR Day 22/Day 1 (95% Cl) | 3.81 (3.58–4.05) |
0.87 (0.79–0.97) |
2.14 (2.02–2.27) |
0.73 (0.66–0.81) |
2.86 (2.74–2.98) |
0.80 (0.74–0.86) |
| Day 43, n | 1076 | 349 | 1080 | 351 | 2156 | 700 |
| GMT (95% Cl) |
170.7 (160.5–181.6) |
11.0 (9.9–12.2) |
97.9 (92.1–104.1) |
16.7 (15.0–18.5) |
130.6 (124.8–136.6) |
13.7 (12.6–14.8) |
| GMR Day 43/Day 1 (95% Cl) | 12.70 (11.94–13.51) |
0.82 (0.73–0.91) |
4.90 (4.61–5.20) |
0.83 (0.75–0.92) |
7.96 (7.61–8.33) |
0.83 (0.77–0.90) |
| Day 183, n | 1025 | 341 | 1054 | 346 | 2079 | 687 |
| GMT (95% Cl) |
20.4 (19.3–21.6) |
6.8 (6.1–7.4) |
19.3 (18.2–20.4) |
8.6 (7.8–9.5) |
20.0 (19.2–20.8) |
7.7 (7.2–8.2) |
| GMR Day 183/Day 1 (95% Cl) | 1.53 (1.44–1.61) |
0.51 (0.46–0.56) |
0.97 (0.91–1.02) |
0.43 (0.39–0.47) |
1.22 (1.17–1.27) |
0.47 (0.44–0.50) |
Abbreviations: CI, confidence interval; GMR, geometric mean ratio; GMT, geometric mean titer; HI, hemagglutination inhibition.